US 12,344,621 B2
CGRP antagonist compounds
Giles Albert Brown, Cambridge (GB); Miles Stuart Congreve, Cambridge (GB); Stephen Paul Watson, Cambridge (GB); Julie Cansfield, Cambridge (GB); Michael Alistair O'Brien, Cambridge (GB); Francesca Deflorian, Cambridge (GB); Gregory R. Ott, North Wales, PA (US); Nigel Alan Swain, Cambridge (GB); Andrew David Cansfield, Cambridge (GB); John Andrew Christopher, Cambridge (GB); and Andrea Bortolato, Cambridge (GB)
Assigned to Nxera Pharma UK Limited, Cambridge (GB)
Appl. No. 17/617,873
Filed by Nxera Pharma UK Limited, Cambridge (GB)
PCT Filed Jun. 12, 2020, PCT No. PCT/GB2020/051428
§ 371(c)(1), (2) Date Dec. 9, 2021,
PCT Pub. No. WO2020/249969, PCT Pub. Date Dec. 17, 2020.
Claims priority of application No. 1908420 (GB), filed on Jun. 12, 2019.
Prior Publication US 2022/0306651 A1, Sep. 29, 2022
Int. Cl. C07D 498/22 (2006.01); A61K 31/438 (2006.01); A61P 25/06 (2006.01)
CPC C07D 498/22 (2013.01) 31 Claims
 
1. A compound of Formula (1):

OG Complex Work Unit Chemistry
or a salt thereof, wherein;
A1, A2 and the atoms to which they are attached together represent an optionally substituted bicyclic or monocyclic ring system;
Q is a bond or 0;
X is O or NH;
R1 is H, C1-3 alkyl or halo;
R2 is H or C1-3 alkyl;
R3 is H or C1-3 alkyl;
and L is a C4-15 linker group, wherein one, two or three, but not all, of the carbon atoms of the linker group may be optionally replaced by a heteroatom selected from O and N.